RAPT Q3 2022 Earnings — RAPT Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RAPTRAPT Therapeutics, Inc.

$959M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$22M

Net Income

-$21M

EPS (Diluted)

$-5.04

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$209M

Total Liabilities

$20M

Stockholders' Equity

$189M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$966,000	-100.0%
Gross Profit	$0	$966,000	-100.0%
Operating Income	-$22M	-$19M	-17.0%
Net Income	-$21M	-$19M	-13.9%